314267-84-0

Upstream product

• 314267-83-9 4-(5-isoxazolyl)benzonitrile 
• 917-54-4 methyllithium 

Downstream Products

• 314268-43-4 1,1-dimethylethyl[1-[4-(5-isoxazolyl)phenyl]-1-methylethyl]carbamate 
• 314268-12-7 C₂₇H₃₁N₅O₄ 
• 314268-09-2 C₃₂H₃₇N₇O₂ 
• 314268-15-0 4-[4-(1-tert-butoxycarbonylamino-1-methylethyl)phenyl]-5-cyano-N-[3-(2-morpholinoethyl)phenyl]pyrimidine-2-amine 
• 314268-17-2 C₂₇H₃₁N₅O₃ 
• 314268-08-1 1,1-dimethylethyl[1-[4-[5-cyano-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]-amino]-4-pyrimidinyl]phenyl]-1-methylethyl]carbamate 
• 314268-06-9 C₂₇H₃₁N₅O₃ 
• 314267-82-8 1-[4-(1-tert-butoxycarbonylamino-1-methylethyl)phenyl]-2-cyano-3-dimethyl-aminopropen-1-one 
• 314268-44-5 1,1-dimethylethyl [1-[4-(cyanoacetyl)phenyl]-1-methylethyl]carbamate 

Relevant academic research and scientific papers

Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile

(Chemical Equation Presented) The preparation of the selective VEGF-R2 kinase inhibitor 10 (JNJ-17029259) is described in which the key precursor, 4-(5-isoxazolyl)benzonitrile, undergoes clean transformation to the corresponding cumylamine derivative with

4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation

A novel series of 4-aryl-5-cyano-2-aminopyrimidines were synthesized and found to have potent VEGF-R2 kinase inhibitory activity. Structure-activity relationships were investigated and compound 14a was shown to be efficacious in a mouse model of corneal neovascularization.